Form 4: Inozyme Pharma CEO Douglas Treco Reports Stock Option Grant
SEC Form 4 Filing
Inozyme Pharma CEO Douglas Treco reports the acquisition of stock options.
Summary
- Douglas A Treco, CEO of Inozyme Pharma, Inc., filed a Form 4 on March 15, 2024, reporting a transaction.
- On March 13, 2024, Treco was granted stock options to purchase 300,000 shares of Inozyme Pharma's common stock at an exercise price of $5.77.
- The options vest in equal monthly installments over four years from the grant date and expire on March 12, 2034.
- Following the transaction, Treco directly owns derivative securities consisting of 300,000 stock options.
Sentiment
Score: 7
Explanation: The sentiment is neutral to slightly positive as it reflects standard executive compensation practices.
Positives
- The grant of stock options to the CEO aligns his interests with those of the shareholders, incentivizing him to increase the company's value.
Industry Context
Stock option grants are a common form of executive compensation in the pharmaceutical industry, aligning management's interests with those of shareholders.
Stakeholder Impact
- The stock option grant could potentially benefit shareholders if the CEO successfully increases the company's value.
Key Dates
| Date | Description |
|---|---|
| 03/13/2024 | Date of stock option grant |
| 03/15/2024 | Date Form 4 was signed |
| 03/12/2034 | Expiration date of the stock options |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.